The chemoattractant CCL2 molecule has been involved in several cancers for inducing MDSC/TAM tumor infiltration and targeting this chemokine with anti-CCL2 antibodies and/or inhibitors of its major ligand, CCR2, have improved tumor regression in pre-clinical models of several cancers [9,10,11]. The gene discussed is CCL2; the disease is neoplasm.